# Nephrocare Health Services share price today (Nephrocare Health Services Ltd, NSE: NEPHROPLUS)

> Nephrocare Health Services share price today: ₹624.60 at the NSE close on 3 November 2026, up 39.1% in a year. Nephrocare Health Services (NSE: NEPHROPLUS) is worth ₹6,276 crore, trades at a P/E of 73.7 and has closed between ₹449.15 and ₹765.35 over the past 52 weeks. > Nephrocare Health Services Ltd's results are improving, while its P/E is near the low end of its own history over 11 months, higher than only 13% of past readings. NEPHROPLUS · Hospitals/Medical Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/nephrocare-health-services-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹624.60 (+39.1% in a year)
- P/E: 73.7× (lower than 87% of the last 11 months)
- Revenue (Jun 2026): ₹282 Cr (+23.7% on a year ago)
- Profit (Jun 2026): ₹32.0 Cr (+33.3% on a year ago)
- Operating margin: 21.0% (flat on a year ago)
- ROCE: 15%, FY26
- ROIC: 15.8%, against a 12.0% cost of capital: +3.8 points
- Profit that came in as cash: 246%, last 3 years

The main question: the share price moved +39.1% in a year while yearly earnings per share moved −88.1%. The difference came from the market paying a higher multiple. ## What is the Nephrocare Health Services share price today? Nephrocare Health Services Ltd's share price was ₹624.60 at the close on 3 November 2026. It has been rising for 41 weeks. That is 0.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Since its first close in our records, on 19 December 2025, it has traded between ₹449 and ₹765, and at that close it sat 55% of the way up from that low. Over the last 11 months the share price moved +39% while the NIFTY 500 moved −8%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Nephrocare Health Services this quarter? 5 points in one quarter. 1. Promoters cut their stake by 5.5 points in one quarter From 63.9% to 58.3% in the September 2026 quarter. ## What are Nephrocare Health Services' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Nephrocare Health Services reported revenue of ₹282 crore, up 23.7% from ₹228 crore a year earlier, and a profit of ₹32.0 crore, up 33.3% from ₹24.0 crore. ### Nephrocare Health Services results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹282 crore | ₹228 crore | +23.7% |
| Profit | ₹32.0 crore | ₹24.0 crore | +33.3% |
| Earnings per share | ₹3.19 | ₹13.10 | −75.6% |
| Operating margin | 21.0% | 21.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Nephrocare Health Services' management discussed these results on a call held on 12 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Nephrocare Health Services share price history? Nephrocare Health Services closed at ₹624.60 on 3 November 2026, up 39.1% from ₹449.15 a year earlier (19 December 2025). Its highest weekly close since December 2025 was ₹765.35 on 11 September 2026. ### Nephrocare Health Services share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹596.45 | +4.7% |
| 1 month ago · 1 Oct 2026 | ₹648.95 | −3.8% |
| 6 months ago · 30 Apr 2026 | ₹529.25 | +18.0% |
| 1 year ago · 19 Dec 2025 | ₹449.15 | +39.1% |
| Earliest and lowest weekly close in our records · 19 Dec 2025 | ₹449.15 | +39.1% |
| Highest weekly close since December 2025 · 11 Sep 2026 | ₹765.35 | −18.4% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (55 weekly closes from 19 December 2025 to 3 November 2026.)

## What is the latest news on Nephrocare Health Services? 3 Nov 2026: Nephrocare Health Services closed at ₹624.60, up 4.7% on the week and down 3.8% on the month. 12 Aug 2026: Nephrocare Health Services held its results call for April to June 2026. Management guided: Medium-term revenue growth of 15-20% over the next 3-5 years. ### Earlier

- Results for April to June 2026: Revenue up 23.7% and profit up 33.3% on a year earlier. ## What dividend does Nephrocare Health Services pay? Nephrocare Health Services has paid no dividend on the NSE since its first NSE close in our records (19 December 2025), the start of the period we checked. No. Nephrocare Health Services Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Nephrocare Health Services management say on the latest results call? On the call for April to June 2026, held on 12 August 2026, Nephrocare Health Services' management guided: Medium-term revenue growth of 15-20% over the next 3-5 years. > “We will not pursue business that does not meet our return thresholds.”
> Rohit Singh, on the call for April to June 2026

### What management guided

- India clinic additions of 40-50 annually and Philippines additions of 10-15 annually. - New international market launch every 12-18 months. - NIDA first training batch begins in Q3. - Saudi formal tendering expected to begin in 2 months. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/59222/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 12 August 2026.)

## What to watch in Nephrocare Health Services' next results? When Nephrocare Health Services reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Philippines additions - check integration, operating contribution and utilization progression across the acquired centers. - What to check (from the call)
- Philippines additions - check integration, operating contribution and utilization progression across the acquired centers. - Adjusted operating margin - check whether procurement, supplier and utilization benefits persist after the initial RFID benefit. - AR days and ECL provisioning - check whether collection improvement lasts and credit-loss pressure remains controlled. ## Which stock lists is Nephrocare Health Services on? Nephrocare Health Services is not on any of our India lists this week. ## Is Nephrocare Health Services profitable? Nephrocare Health Services Ltd earned ₹32.0 Cr of net profit in the Jun 2026 quarter, +33.3% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹77.0 Cr. Over 5 years profit has grown 138.4% a year on average. That is 11.3% of the quarter's revenue. The same quarter a year earlier earned ₹24.0 Cr. For the full year, FY26 profit was ₹77.0 Cr (+14.9% on the year before). Why profit moved: revenue changed +23.7% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +37.8% and revenue +25.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Nephrocare Health Services make, and is it growing? Nephrocare Health Services Ltd reported ₹282 Cr of revenue in the Jun 2026 quarter, +23.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 28.4% a year on average. The last full year, FY26, came in at ₹999 Cr. The last four reported quarters add to ₹1,054 Cr. FY26 revenue was ₹999 Cr, +32.1% on the year before. Recent pace: the last four quarters grew +25.7% on average, against 28.4% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every ₹100 of sales does Nephrocare Health Services keep? Nephrocare Health Services Ltd's operating margin was 21.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 6 years it has been between 5.0% and 23.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.5 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Nephrocare Health Services' profit turning into cash? Over the last 3 years, 246% of Nephrocare Health Services Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹233 Cr of operating cash against ₹77.0 Cr of profit. After ₹212 Cr of spending on assets, ₹21.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 246% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.1× depreciation over three years. The next section checks what that spending is building. ## Where does Nephrocare Health Services' cash go? Nephrocare Health Services Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 116 days in FY26, up from 110 days in FY21. It spent ₹469 Cr on assets over the last 3 years. Customers take 116 days to pay, and stock sits for 53 days on average. At FY26 sales of ₹999 Cr, each day of that cycle ties up about ₹2.7 Cr, so roughly ₹317 Cr is tied up in the business at any time. FY26: customers took 116 days to pay and stock sat for 53 days, about 1.7 months of sales sitting as stock, for a full cycle of 116 days, longer than FY21's 110. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 53 days. Customers pay about 116 days after that. Suppliers are paid at 230 days. Together that makes the 116-day cycle. Spending on assets: ₹469 Cr over the last 3 years, against ₹219 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹6.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Nephrocare Health Services' P/E ratio, and how does it compare with its own history? Nephrocare Health Services Ltd's P/E is 73.7×, near the low end of its own history: it has been lower only 13% of the time. Its usual P/E (the middle reading) is 82.1×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved −88.1% while the price moved +39.1%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Nephrocare Health Services business getting better or worse? Nephrocare Health Services Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Nephrocare Health Services earn on its capital? Nephrocare Health Services Ltd earned a ROCE of 15% in FY26. That is up from a low of −4% in FY22. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.7% net margin and 0.68× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.7% net margin × 0.68× asset turnover × 1.31× leverage (assets divided by equity) ≈ 6.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 15.8% − 12.0% = +3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Nephrocare Health Services have too much debt? Nephrocare Health Services Ltd has total debt of ₹80.0 Cr against shareholder equity of ₹1,116 Cr as of Jun 2026, so its debt is 0.07× its equity, which is very little. Year by year, that ratio went from 0.44 in FY25 to 0.07 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Nephrocare Health Services shareholding pattern? No group of Nephrocare Health Services Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Nephrocare Health Services from balance-sheet trouble? For Nephrocare Health Services Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Nephrocare Health Services rank in its industry? 47.9 out of 100, rank 3 of 7 in Hospitals/Medical Services, with 55% of the evidence available. Nephrocare Health Services Ltd scores 47.9 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 3. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 25.6 + 9.5 + 12.8 = 47.9 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Nephrocare Health Services compared with? Nephrocare Health Services ranks 3 of 7 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 47.9 out of 100. 1. [Dr Agarwals Health Care Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-health-care-ltd) AGARWALEYE · turning · Evidence leans up · 60% evidence 60.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 22.9% · Profit 42.3% · Operating margin change 2 points · 95% evidence Capital efficiency 9.6/25 · ROCE 10.9% · Operating margin 28% · 76% evidence Valuation 8.5/20 · P/E 109× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 12.1% · 1 year 0.6% · 25% evidence · 8 of 12 weeks ahead Exact sum: 30 + 9.6 + 8.5 + 12.5 = 60.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Unihealth Hospitals Ltd](https://www.sectoralpha.in/stocks/unihealth-hospitals-ltd) UNIHEALTH · quiet · Too little evidence to rank firmly · 51% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.8/35 · Revenue n/a · Profit n/a · Operating margin change -4 points · 26% evidence Capital efficiency 18.1/25 · ROCE 24.5% · Operating margin 34% · 76% evidence Valuation 10.5/20 · P/E 34.1× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 6.9% · Lead over NIFTY 500 22.3% · 1 year 227.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 16.8 + 18.1 + 10.5 + 14 = 59.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. Nephrocare Health Services Ltd this page NEPHROPLUS · quiet · Too little evidence to rank firmly · 55% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/43.75 · Revenue n/a · Profit n/a · Operating margin change 0 points · 48% evidence Capital efficiency 9.5/31.25 · ROCE 15.3% · Operating margin 21% · 100% evidence Valuation 12.8/25 · P/E 72.6× · PEG 1.55 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 25.6 + 9.5 + 12.8 = 47.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 4. [Gaudium IVF and Women Health Ltd](https://www.sectoralpha.in/stocks/gaudium-ivf-and-women-health-ltd) GAUDIUMIVF · quiet · Evidence leans down · 63% evidence 47.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.8/43.75 · Revenue 16.3% · Profit 10.6% · Operating margin change -16.5 points · 100% evidence Capital efficiency 19.2/31.25 · ROCE 29.5% · Operating margin 12.5% · 100% evidence Valuation 13.8/25 · P/E 33.3× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 14.8 + 19.2 + 13.8 = 47.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 5. [Gujarat Kidney & Super Speciality Ltd](https://www.sectoralpha.in/stocks/gujarat-kidney-super-speciality-ltd) GKSL · breaking out · Evidence leans down · 63% evidence 47.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/43.75 · Revenue 100% · Profit 36.7% · Operating margin change -32.1 points · 100% evidence Capital efficiency 11.8/31.25 · ROCE 14.5% · Operating margin 24.4% · 100% evidence Valuation 11.3/25 · P/E 81.3× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.9 + 11.8 + 11.3 = 47 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 6. [KRM Ayurveda Ltd](https://www.sectoralpha.in/stocks/krm-ayurveda-ltd) KRMAYURVED · quiet · Too little evidence to rank firmly · 38% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/43.75 · Revenue n/a · Profit n/a · Operating margin change 12 points · 32% evidence Capital efficiency 24.4/31.25 · ROCE 35.3% · Operating margin 37.2% · 95% evidence Valuation 14.4/25 · P/E 19.1× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.1 + 24.4 + 14.4 = 61.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Park Medi World Ltd](https://www.sectoralpha.in/stocks/park-medi-world-ltd) PARKHOSPS · quiet · Too little evidence to rank firmly · 38% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/43.75 · Revenue n/a · Profit n/a · Operating margin change 0 points · 45% evidence Capital efficiency 19.1/31.25 · ROCE 19.5% · Operating margin 26% · 76% evidence Valuation 12.5/25 · P/E 34.2× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 22.5 + 19.1 + 12.5 = 54.1 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals/Medical Services](https://www.sectoralpha.in/sectors/hospitals-medical-services), all 7 compared on one page. ## Which companies are close to Nephrocare Health Services in size? Nephrocare Health Services is the 3rd largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Agarwals Health Care and Park Medi World. Just below it: Gujarat Kidney & Super Speciality, Unihealth Hospitals, Gaudium IVF and Women Health and KRM Ayurveda. ### Hospitals/Medical Services companies close in size

1. [Dr Agarwals Health Care Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-health-care-ltd) ₹16,144 crore
2. [Park Medi World Ltd](https://www.sectoralpha.in/stocks/park-medi-world-ltd) ₹9,490 crore
3. Nephrocare Health Services Ltd ₹6,180 crore
4. [Gujarat Kidney & Super Speciality Ltd](https://www.sectoralpha.in/stocks/gujarat-kidney-super-speciality-ltd) ₹1,288 crore
5. [Unihealth Hospitals Ltd](https://www.sectoralpha.in/stocks/unihealth-hospitals-ltd) ₹875 crore
6. [Gaudium IVF and Women Health Ltd](https://www.sectoralpha.in/stocks/gaudium-ivf-and-women-health-ltd) ₹771 crore
7. [KRM Ayurveda Ltd](https://www.sectoralpha.in/stocks/krm-ayurveda-ltd) ₹479 crore

[All 7 Hospitals/Medical Services companies, largest first](https://www.sectoralpha.in/sectors/hospitals-medical-services#all-companies)

### Companies close in size in other industries

1. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore · Pharma - API & CRAMS
2. [DCB Bank Ltd](https://www.sectoralpha.in/stocks/dcb-bank-ltd) ₹6,206 crore · Banks - Private
3. Nephrocare Health Services Ltd ₹6,180 crore
4. [Shrem InvIT](https://www.sectoralpha.in/stocks/shrem-invit) ₹6,176 crore · Infrastructure Investment Trusts
5. [Waterways Leisure Tourism Limited](https://www.sectoralpha.in/stocks/waterways-leisure-tourism-limited) ₹6,166 crore

## What else do people ask about Nephrocare Health Services? ### What is Nephrocare Health Services's share price today? Nephrocare Health Services Ltd's share price is ₹624.60, +39.1% over the past year. The whole company is worth ₹6,276 Cr on the market. In the last 52 weeks it traded between ₹449 to ₹765; today it is 55% of the way up from the low, 0.5% above its 200-day average (as of 3 November 2026). ### What were Nephrocare Health Services's latest quarterly results? Nephrocare Health Services Ltd reported revenue of ₹282 Cr and net profit of ₹32.0 Cr for the Jun 2026 quarter. Revenue rose 23.7% and profit rose 33.3% compared with a year earlier. Earnings per share were ₹3.19. The operating margin was 21.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Nephrocare Health Services's market cap? Nephrocare Health Services Ltd's market capitalisation is ₹6,276 Cr at a share price of ₹624.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Nephrocare Health Services performing? Nephrocare Health Services Ltd's share price has been rising for 41 weeks. In its latest quarter, revenue rose 23.7% and profit rose 33.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 3 November 2026). ### Is Nephrocare Health Services in an uptrend? Yes, the price has been rising for 41 weeks (stage 2 of 4), 0.5% above its 200-day average, and 55% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 3 November 2026). ### Will Nephrocare Health Services's share price go up? This page does not forecast Nephrocare Health Services Ltd's share price. What it shows instead: the share price is ₹624.60, and it has been rising for 41 weeks. Its P/E of 73.7× is higher than 13% of its own last 1 years (as of 3 November 2026). ### Who owns Nephrocare Health Services? Promoters own 58.3% of Nephrocare Health Services Ltd, foreign institutions 11.7%, domestic institutions 8.1% and the public 21.9% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Where is Nephrocare Health Services in its business cycle? Nephrocare Health Services Ltd's FY26 operating margin was 23.0%, against a 6-year range of 5.0% to 23.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Nephrocare Health Services story? The main question: the share price moved +39.1% in a year while yearly earnings per share moved −88.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Nephrocare Health Services a stock worth studying right now? What the numbers show: Nephrocare Health Services Ltd's results are improving, while its P/E is near the low end of its own history over 11 months, higher than only 13% of past readings. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Nephrocare Health Services share price forecast for 2026? What management itself guided: Medium-term revenue growth of 15-20% over the next 3-5 years. This is research, not advice. We’re not SEBI-registered.